Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

416
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
416
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

478
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
478
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

482
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
482
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity04:47

Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity

2.4K
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug...
2.4K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

5.3K
Described is a protocol to establish a Doxorubicin-induced dilated cardiomyopathy (DCM) model in mice via long-term intraperitoneal injection of...
5.3K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

10.3K
A method to generate a doxorubicin-induced cardiomyopathy model in adult zebrafish (Danio rerio) is described here. Two alternative ways of intraperitoneal injection are presented and conditions to reduce variations among different experimental groups are...
10.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features, diagnostic difficulties and therapeutic enlightenment of adult-onset multisystem Langerhans cell histiocytosis complicated with panhypopituitarism and central diabetes insipidus: a case report and systematic literature review.

Frontiers in oncology·2026
Same author

Evidence summary of best practices for prevention and management of postpartum hemorrhage in obstetric clinical practice.

Frontiers in medicine·2026
Same author

MR Lymphangiography for Diagnosis of Lower Extremity Lymphedema: Suppressing Venous Signal Interference Using Deep Learning.

Radiology·2026
Same author

PhenolFingerprint DB: an open-access platform for phenolic fingerprinting, quantification, and automated species authentication, validated on 93 floral and herbal plants.

Food chemistry·2026
Same author

Variable efficacy of the non-covalent KRAS<sup>G12D</sup> inhibitor (MRTX-1133) with obesity in murine pancreatic cancer.

NPJ precision oncology·2026
Same author

[Association between mixed exposure to 11 urinary metal elements and the risk of thyroid cancer: a case-control study].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences·2026

Related Experiment Video

Updated: Jan 20, 2026

Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
04:47

Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity

Published on: April 30, 2023

2.4K

Doxorubicin cardiomyopathy.

Kanu Chatterjee1, Jianqing Zhang, Norman Honbo

  • 1Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242-1081, USA. kanu-chatterjee @ uiowa.edu

Cardiology
|December 18, 2009
PubMed
Summary

Doxorubicin cardiomyopathy is a serious condition with high mortality. Despite extensive research, effective treatments or preventive strategies for this chemotherapy-induced heart disease remain undiscovered.

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Doxorubicin cardiomyopathy is a lethal condition, with a 50% mortality rate once congestive heart failure develops.
  • Significant research has elucidated the mechanisms and pathophysiology of this chemotherapy-induced cardiac toxicity.
  • Currently, no effective treatments exist for established doxorubicin cardiomyopathy.

Purpose of the Study:

  • To review the current understanding of doxorubicin cardiomyopathy.
  • To highlight the unmet need for effective therapeutic and preventive strategies.
  • To discuss ongoing research directions in managing this adverse effect of cancer therapy.

Main Methods:

  • Literature review of established and ongoing research on doxorubicin cardiomyopathy.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.3K

Related Experiment Videos

Last Updated: Jan 20, 2026

Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
04:47

Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity

Published on: April 30, 2023

2.4K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.3K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.3K
  • Analysis of clinical outcomes and mortality associated with doxorubicin treatment.
  • Synthesis of current knowledge on pathophysiology and treatment strategies.

    • Main Results:

    • Doxorubicin-induced cardiomyopathy is a significant clinical challenge in cancer patients.
    • Despite extensive research, no clinically applicable preventive or therapeutic interventions are currently available.
    • The development of effective treatments remains a critical unmet need in oncology and cardiology.

    Conclusions:

    • Established doxorubicin cardiomyopathy carries a poor prognosis, emphasizing the urgent need for novel interventions.
    • Further research is crucial to discover and validate effective preventive and therapeutic strategies for doxorubicin-induced cardiotoxicity.
    • Bridging the gap between research findings and clinical application is essential for improving patient outcomes.